Clinical trials
Phase 2 Multiple Myeloma trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
60 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 4 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 6 |
| 2017 | 4 |
| 2018 | 5 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 2 |
| 2024 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 42 |
| Terminated | 7 |
| Recruiting | 5 |
| Active, not recruiting | 3 |
| Withdrawn | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Canadian Myeloma Research Group | 5 |
| University Health Network, Toronto | 5 |
| Amgen | 4 |
| Janssen Research & Development, LLC | 4 |
| Bristol-Myers Squibb | 3 |
| Celgene | 3 |
| NCIC Clinical Trials Group | 3 |
| Novartis Pharmaceuticals | 3 |
| AHS Cancer Control Alberta | 2 |
| AbbVie | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Myeloma | 60 |
| Recurrence | 11 |
| Neoplasms, Plasma Cell | 8 |
| Neoplasms | 7 |
| Lymphoma | 3 |
| Lymphoma, Non-Hodgkin | 3 |
| Amyloidosis | 2 |
| Hematologic Diseases | 2 |
| Kidney Neoplasms | 2 |
| Biliary Tract Neoplasms | 1 |
Trials
Showing 1 to 25 of 60. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.